Benzinga | Sep 7, 2021 06:55AM EDT

Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy

* Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD).

* Spark Therapeutics is a part of Roche Holdings AG (OTC:RHHBY).

* Under the deal, Spark Therapeutics has the option to license the exclusive worldwide rights of NeuExcell's HD program.

* Under the Option, NeuExcell said it is eligible to receive upfront, license fees, R&D, and sales milestone payments up to about $190 million, plus product royalties.

* Under terms, Spark Therapeutics will get access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities.

* NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the program.

* Price Action: RHHBY shares closed at $49.75 on Friday.